Visit www.tigersoft.com - See how to beat the Wall Street Pros at their own game, insider trading.
More reading FDA Insider Trading: Time for an Overhaul?
FACTBOX-Trades made by FDA chemist in insider trading caseat Reuters (Tue, Mar 29)
LEADING BIOTECH STOCKS
DUSA DUSA Pharmaceuticals Inc. 85 employees
| BIIB Biogen
Idec Inc. 4850 empoloyess Website: http://www.biogenidec.com
therapeutics in the areas of neurology, immunology, hemophilia, and oncology
Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe plaque psoriasis in adult patients. The company?s products under Phase III consist of FAMPYRA, an oral compound that is being developed as a treatment to enhance walking ability in people with MS; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis; Recombinant Factors VIII and IX for the treatment of hemophilia; and GA101, a monoclonal antibody for the treatment of chronic lymphocytic leukemia and NHL
| ATRC AtriCure,
Inc. 220 employees Website: http://www.atricure.com
Cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac tissue.
| ARQL ArQule Inc.
115 employees Website: http://www.arqule.com
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer
Many presentations recently to stock brokers.
| ABMD Abiomed
Inc. 365 employees Website: http://www.abiomed.com
Medical devices that provide circulatory support to acute heart failure
4/15/2011 The federal Center for Medicare and Medicaid services earlier in the day expanded the uses for which Abiomed's Impella 2.5 a device that assists patients' hearts is indicated. The fedreal agency said the device is now appropriate for patients with: cardiogenic shock; severe decompensated heart failure; acute myocardial infarction; bridge to transplant or high risk percutaneous coronary intervention.
Laboratory Corp. of America Holdings 31,000
RMPLOYEES Website: http://www.labcorp.com
Inndependent clinical laboratory company
Progenics Pharmaceuticals Inc. 159 employees
injection for the treatment of opioid-induced constipation in advanced illness patients
receiving palliative care. It is also conducting a Phase I clinical trial of a human
monoclonal antibody-drug conjugate directed against prostate specific membrane antigen
(PSMA), a protein found at high levels on the surface of prostate cancer cells, as well as
in blood vessels supplying other solid tumors.
ViroPharma Incorporated 232 EMPLOYEES Website: http://www.viropharma.com
product line includes Cinryze for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema; and Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Its products in development include C1 esterase inhibitor to identify further therapeutic uses and potential additional indications and other modes of administration for the treatment of HAE and other C1 mediated diseases; a non-toxigenic strain of C. difficile for the treatment and prevention of CDI.; and Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus infections related to transplant.
April 5, 2011
| WST West Pharmaceutical
Services, Inc. 6600 EMPLOYEES Website: http://www.westpharma.com
manufactures and sells components and systems for injectable drug delivery and plastic packaging, and delivery system components for the pharmaceutical, healthcare, and consumer products industries